Ivosidenib

Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of isocitrate dehydrogenase-1, which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials.